Possible standard adjuvant therapies for TTP are rituximab; the monoclonal antibody against CD20 on the surface of B cells, which inhibits the production of disease-related ADAMTS13 inhibitors by depleting B lymphocytes; and caplacizumab, a humanized bivalent anti-vWF immunoglobulin fragment that inhibits the interaction between vWF multimers and platelets. The gene discussed is VWF; the disease is thrombotic thrombocytopenic purpura.